POLB 001 TOPICAL trial recruitment update

Summary by AI BETAClose X

Poolbeg Pharma plc announced that recruitment for its POLB 001 TOPICAL trial is progressing well, with eight participants now dosed out of approximately 30 since the first patient was dosed in July 2026. The trial is evaluating POLB 001 as a preventative therapy for Cytokine Release Syndrome in multiple myeloma patients receiving teclistamab, and further clinical sites have expressed interest in joining.

Disclaimer*

UK 100

Latest directors dealings